Clinical Trial

Reduction of Remifentanil-related Complications

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 1, 2023 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2009-10-27; most recent amendment 2023-11-29.
Status change: Active, Not Recruiting → Not Yet Recruiting 2011-10-04
Status change: Not Yet Recruiting → Active, Not Recruiting 2010-05-04
Trial Details
NCT Number NCT01003028
Lead Sponsor Seoul National University Hospital
Conditions Anesthesia
Enrollment 160 participants
Start Date 2024-11-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-01